ACORDA THERAPEUTICS INC (ACOR) Stock Price, Forecast & Analysis
USA - NASDAQ:ACOR - US00484M7002 - Common Stock
ACOR Key Statistics, Chart & Performance
The current stock price of ACOR is 0.661 USD. In the past month the price decreased by -94.67%. In the past year, price decreased by -93.76%.
ACOR Latest News, Press Relases and Analysis
ACOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About ACOR
Company Profile
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Pearl River, New York and currently employs 111 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Company Info
ACORDA THERAPEUTICS INC
Two Blue Hill Plaza
Pearl River NEW YORK 10502 US
CEO: Ron Cohen
Employees: 111
Phone: 19143474300
ACORDA THERAPEUTICS INC / ACOR FAQ
What does ACOR do?
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Pearl River, New York and currently employs 111 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Can you provide the latest stock price for ACORDA THERAPEUTICS INC?
The current stock price of ACOR is 0.661 USD. The price decreased by -24.86% in the last trading session.
Does ACOR stock pay dividends?
ACOR does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACOR stock?
ACOR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How is the valuation of ACORDA THERAPEUTICS INC (ACOR) based on its PE ratio?
ACORDA THERAPEUTICS INC (ACOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-204.57).
What is the employee count for ACOR stock?
ACORDA THERAPEUTICS INC (ACOR) currently has 111 employees.
Can you provide the market cap for ACORDA THERAPEUTICS INC?
ACORDA THERAPEUTICS INC (ACOR) has a market capitalization of 821.03K USD. This makes ACOR a Nano Cap stock.
ACOR Technical Analysis
ACOR Financial Highlights
Over the last trailing twelve months ACOR reported a non-GAAP Earnings per Share(EPS) of -204.57. The EPS decreased by -129.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ACOR Forecast & Estimates
7 analysts have analysed ACOR and the average price target is 10.2 USD. This implies a price increase of 1443.12% is expected in the next year compared to the current price of 0.661.